The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies ...